Affordable Access

Thrombotic reactant markers in non-ST segment elevation acute coronary syndromes treated with either enoxaparin (low molecular weight heparin) or unfractionated heparin.

Authors
  • Gurfinkel, E
  • Duronto, E
  • Colorio, C
  • Bozovich, G
  • Cohen, M
  • Mautner, B
Type
Published Article
Journal
Journal of thrombosis and thrombolysis
Publication Date
Oct 01, 1999
Volume
8
Issue
3
Pages
227–232
Identifiers
PMID: 10500313
Source
Medline
License
Unknown

Abstract

In this subset of patients enrolled in the ESSENCE study, enoxaparin 1 mg/kg ql2hr significantly increased anti-Xa activity above that seen with unfractionated heparin, and reduced thrombin production without prolonging the thrombin time. The high anti-Xa activity achieved with enoxaparin was not associated with a loss of safety.

Report this publication

Statistics

Seen <100 times